Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000-2009

• Published in: The international journal of tuberculosis and lung disease Vol. 19; no. 4; pp. 406 - 412
• Main Authors: van Altena, R., de Vries, G., Haar, C. H., de Lange, W. C. M., Magis-Escurra, C., van den Hof, S., van Soolingen, D., Boeree, M. J., van der Werf, T. S.
• Format: Journal Article
• Language: English
• Published: France International Union Against Tuberculosis and Lung Disease 01.04.2015
• Subjects: Adolescent; Adult; Age Distribution; Antitubercular Agents - therapeutic use; Child; Child, Preschool; Coinfection - therapy; Drug Susceptibility Testing; Drug Therapy, Combination; Female; Follow-Up Studies; HIV; HIV Infections - therapy; Humans; Infant; Infant, Newborn; Male; Mdr-Tb; Middle Aged; Mycobacterium; Mycobacterium tuberculosis - drug effects; Netherlands - epidemiology; Outcome; Public Health; Retrospective Studies; Risk Factors; Sex Distribution; Therapeutic Drug Monitoring; Treatment Outcome; Tuberculosis, Multidrug-Resistant - epidemiology; Tuberculosis, Multidrug-Resistant - therapy; Tuberculosis, Pulmonary - therapy; Young Adult; Netherlands

SETTING: Resistance to the two key anti-tuberculosis drugs isoniazid and rifampicin is a characteristic of multidrug-resistant tuberculosis (MDR-TB). MDR-TB is a scourge requiring toxic, prolonged treatment and is associated with poor outcomes. The Netherlands is a country with a long-standing, inte...